Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.35 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1335604 | 0.87 | ADRA1A (0.48) | ALDH1A1GPR84ADRA1ACHRM1AKR1A1 | |
| SCHEMBL6899434 | 0.86 | GPR84 (0.52) | GPR84CYP1A2MAPK1NPSR1TSHR | |
| SCHEMBL26655946 | 0.86 | TSHR (0.38) | GPR84ADRA1ACHRM1AKR1A1CHRM3 | |
| SCHEMBL21801004 | 0.86 | TSHR (0.38) | GPR84ADRA1ACHRM1AKR1A1CHRM3 | |
| SCHEMBL21801003 | 0.86 | TSHR (0.38) | GPR84ADRA1ACHRM1AKR1A1CHRM3 | |
| SCHEMBL2220335 | 0.85 | GPR84 (0.55) | GPR84CYP1A2MAPK1NPSR1TSHR | |
| SCHEMBL27577255 | 0.84 | MGAM (0.41) | ALDH1A1GPR84ADRA1ACHRM1AKR1A1 | |
| SCHEMBL8878752 | 0.83 | FFAR3 (0.39) | ALDH1A1GPR84ADRA1ATDP1FFAR3 | |
| SCHEMBL9060857 | 0.82 | SLC22A6 (0.41) | ALDH1A1ADRA1ATDP1FFAR3CACNA2D1 | |
| SCHEMBL967149 | 0.82 | ADRA1A (0.48) | ALDH1A1GPR84ADRA1ACHRM1AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117756447-A | High-performance concrete in high-altitude large-temperature-difference environment and preparation method thereof | 中铁二十局集团第三工程有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-117696019-A | Plant fiber-based adsorption material and preparation method and application thereof | 中国科学院赣江创新研究院 | 2024-03-15 | — | — | CN | claimed |
| CN-112739683-B | Preparation method of brivaracetam and intermediate thereof | 上海宣泰医药科技股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117756447-A | High-performance concrete in high-altitude large-temperature-difference environment and preparation method thereof | 中铁二十局集团第三工程有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117696019-A | Plant fiber-based adsorption material and preparation method and application thereof | 中国科学院赣江创新研究院 | 2024-03-15 | — | — | CN | disclosed |
| US-11884623-B2 | Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam | DIVI'S LABORATORIES LTD. (IN) | 2024-01-30 | — | — | US | disclosed |
| EP-4282971-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (R )-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM | Divi's Laboratories Limited (IN) | 2023-11-29 | — | — | EP | disclosed |
| US-20230373914-A1 | PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM | DIVI'S LABORATORIES LTD. (IN) | 2023-11-23 | — | — | US | disclosed |
| CN-112739683-A | Preparation method and intermediate of brivaracetam | 上海宣泰医药科技股份有限公司 | 2021-04-30 | — | — | CN | disclosed |
| WO-2020052545-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATES THEREOF | 上海宣泰医药科技有限公司 | 2020-03-19 | — | — | WO | disclosed |
| WO-2020051796-A1 | PREPARATION METHOD FOR BRIVARACETAM AND INTERMEDIATE THEREOF | 上海宣泰医药科技有限公司 | 2020-03-19 | — | — | WO | disclosed |
| EP-0454444-A1 | Glutarimide derivatives and herbicides | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884623-B2 | Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam | BPGM, MGAM, HPD | ALDH1A1 564/4885GPR84 898/4885ADRA1A 1235/4885 |
| US-20230373914-A1 | PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM | BPGM, MGAM, HPD | ALDH1A1 564/4885GPR84 898/4885ADRA1A 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.